Literature DB >> 21546964

Antitumor properties of histamine in vivo.

Fredrik B Thoren, Johan Aurelius, Anna Martner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21546964     DOI： 10.1038/nm0511-537a

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  10 in total

1.  In-vivo experimental demonstration that hyperhistaminism counteracts tumor-growth.

Authors:  F Dellarovere; G Broccio; A Granata; V Fimiani
Journal:  Oncol Rep       Date:  1994-01       Impact factor: 3.906

Review 2.  Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.

Authors:  Anna Martner; Fredrik B Thorén; Johan Aurelius; Jonas Söderholm; Mats Brune; Kristoffer Hellstrand
Journal:  Expert Rev Hematol       Date:  2010-08       Impact factor: 2.929

3.  Effects of histamine, H1, H2 and Hic receptor antagonists and alpha-fluoromethylhistidine on the growth of human colorectal cancer in the subrenal capsule assay.

Authors:  E Suonio; L Tuomisto; E Alhava
Journal:  Agents Actions       Date:  1994-06

4.  Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.

Authors:  Mats Brune; Sylvie Castaigne; John Catalano; Kurt Gehlsen; Anthony D Ho; Wolf-Karsten Hofmann; Donna E Hogge; Bo Nilsson; Reuven Or; Ana I Romero; Jacob M Rowe; Bengt Simonsson; Ruth Spearing; Edward A Stadtmauer; Jeff Szer; Elisabeth Wallhult; Kristoffer Hellstrand
Journal:  Blood       Date:  2006-03-23       Impact factor: 22.113

5.  Inhibitory effects of tetragastrin and histamine on carcinogenesis in the small intestines of W rats by N-methyl-N'-nitro-N-nitrosoguanidine.

Authors:  M Tatsuta; H Iishi; M Ichii; S Noguchi; H Yamamura; H Taniguchi
Journal:  J Natl Cancer Inst       Date:  1986-02       Impact factor: 13.506

Review 6.  Histamine in cancer immunotherapy: a preclinical background.

Authors:  Kristoffer Hellstrand
Journal:  Semin Oncol       Date:  2002-06       Impact factor: 4.929

Review 7.  Myeloid-derived suppressor cells as regulators of the immune system.

Authors:  Dmitry I Gabrilovich; Srinivas Nagaraj
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

8.  Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b+Ly6G+ immature myeloid cells.

Authors:  Xiang Dong Yang; Walden Ai; Samuel Asfaha; Govind Bhagat; Richard A Friedman; Guangchun Jin; Heuijoon Park; Benjamin Shykind; Thomas G Diacovo; Andras Falus; Timothy C Wang
Journal:  Nat Med       Date:  2010-12-19       Impact factor: 53.440

9.  Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma--results from a randomised phase II trial.

Authors:  F Donskov; M Hokland; N Marcussen; H H Torp Madsen; H von der Maase
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

10.  Decrease in tumour growth by injections of histamine or serotonin in fibrosarcoma-bearing mice: influence of H1 and H2 histamine receptors.

Authors:  C Burtin; P Scheinmann; J C Salomon; G Lespinats; P Canu
Journal:  Br J Cancer       Date:  1982-01       Impact factor: 7.640
  10 in total
  3 in total

Review 1.  Histamine: an undercover agent in multiple rare diseases?

Authors:  Almudena Pino-Ángeles; Armando Reyes-Palomares; Esther Melgarejo; Francisca Sánchez-Jiménez
Journal:  J Cell Mol Med       Date:  2012-09       Impact factor: 5.310

Review 2.  Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.

Authors:  Robert Wesolowski; Joseph Markowitz; William E Carson
Journal:  J Immunother Cancer       Date:  2013-07-15       Impact factor: 13.751

3.  Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.

Authors:  Anna Martner; Anna Rydström; Rebecca E Riise; Johan Aurelius; Harald Anderson; Mats Brune; Robin Foà; Kristoffer Hellstrand; Fredrik B Thorén
Journal:  Oncoimmunology       Date:  2015-05-05       Impact factor: 8.110
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.